

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
Peter NAWROTH <i>et al.</i>	)	Group Art Unit: 1632
Application No.: 09/423,712	)	Examiner: Q. Janice Li
Filed: August 25, 2000	)	Confirmation No.: 7074
For: TISSUE FACTOR FOR INFLUENCING	)	
BLOOD VESSEL FORMATION	)	

**INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☐ No additional fee for submission of an IDS is required.
- ☒ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☒ A check in the amount of \$ 180.00 is enclosed for the fee due.


The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: October 20, 2003

By:

  
Deborah H. Yeh  
Registration No. 45,904

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
Peter NAWROTH <i>et al.</i>	)	Group Art Unit: 1632
	)	
Application No.: 09/423,712	)	Examiner: Q. Janice Li
	)	
Filed: August 25, 2000	)	Confirmation No.: 7074
	)	
For: TISSUE FACTOR FOR	)	
INFLUENCING BLOOD VESSEL	)	
FORMATION	)	

**FOURTH**  
**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56,  
Applicants hereby submit the following information in conformance with 37 C.F.R.  
§§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.


The documents are being submitted after a first Office Action on the merits but  
prior to the closing of prosecution, therefore under 37 C.F.R. § 1.97(c) the fee set forth in  
37 C.F.R. § 1.17(p) is enclosed.

A fee in the amount of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is  
enclosed.

To assist the Examiner, the documents are listed on the attached form PTO-1449.  
It is respectfully requested that an Examiner-initialed copy of this form be returned to the  
undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Deborah H. Yelton  
Registration No. 45,904

10/23/2003-SSITHIB1-00000083-09423712

01-FCF1806

180.00-00

Date: October 20, 2003

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

ATTORNEY'S DKT NO

012627-028

APPLICATION NO.

09/423.712

**APPLICANT**

Peter NAWROTH *et al.*

FILING DATE

August 25, 2000

GROUP

1632

Examiner  
Initials

Document  
NumberKind Code  
(if known)Name of Patentee or Applicant  
of Cited Document

Issue/Publication  
Date  
(MM-DD-YYYY)

Examiner  
InitialsDocument  
NumberKind Code  
(if known)

Country

Date of Publication  
(MM-DD-YYYY)

Translation	
Yes	No

Examiner  
Initials

Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

BELLON *et al.*, "Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial.", *Hum Gene Ther.*, 1997, 8(1):15-25; Mary Ann Liebert, Inc., Larchmont, New York (Abstract only).

CROMBLEHOLME, "Adenoviral-mediated gene transfer in wound healing.", *Wound Repair Regen.*, November-December, 2000; 8(6):460-72; Blackwell Publishing, Oxford, England (Abstract only).

KAY *et al.*, "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.", *Nat Genet.* 2000, 24(3):201-2, 2000, Nature Publishing Group, London, England (Abstract only).

MAGOVERN *et al.*, "Primary inflammatory fibrosarcoma of the esophagus", Ann Thorac Surg., 1996, 62(6):1848-50, Elsevier Science, Inc., New York (Abstract only).

MERROUCHE *et al.*, "Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.", J Clin Oncol, 1995; 13(2):410-8; American Society of Clinical Oncology, Alexandria, Virginia (Abstract only).

MILES *et al.*, "Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy.", *Hum Gene Ther.*, November, 2001, 12(16):1955-67, Mary Ann Liebert, Inc., Larchmont, New York (Abstract only)

MORRISSEY *et al.*, "Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade", Cell, July 3, 1987, 50(1):129-35, Cell Press, Cambridge, England (Abstract only).

MÜHLHAUSER *et al.*, "VEGF<sub>165</sub> Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo", *Circulation Research*, 1995, 77:1077-1086; Lippincott, Williams and Wilkins, Baltimore, Maryland.

REDFIELD *et al.*, "A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection," N Engl J Med., 1991; 324(24):1677-84; Mass Medical Society, Boston, Massachusetts (Abstract only).

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO.	APPLICATION NO.
	012627-028	09/423,712
	APPLICANT	
	Peter NAWROTH <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	August 25, 2000	1632

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	SYLVESTER <i>et al.</i> , "Adenoviral-mediated gene transfer in wound healing: acute inflammatory response in human skin in the SCID mouse model", Wound Repair Regen, January-February, 2000, Vol. 8, Issue 1, Page 36; Blackwell Publishing, Oxford, England (Abstract only).
	TAN <i>et al.</i> , "IL-2 gene therapy of advanced lung cancer patients.", Anticancer Res., July-August, 1996; 16(4A):1993-8; International Conference of Anticancer Research, Attiki, Greece (Abstract only).
	VERMA <i>et al.</i> , "Gene therapy - promises, problems and prospects", Nature, (1997), 89, 239-242, Nature Publishing Group, London, England.
	VOGT <i>et al.</i> , "Genetically modified keratinocytes transplanted to wounds reconstitute the epidermis", Proc. Natl. Acad. Sci. USA, September, 1994; pp. 9307-9311, Vol. 91, National Academy of Sciences, Washington, DC.
	ZABNER <i>et al.</i> , "Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis.", Cell, 1993, 75(2):207-16, Cell Press, Cambridge, England (Abstract only).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.